Fengming Zou

Hefei, 230031, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Discovery of pyrazole derivative IHMT-140 as a pancreatic cancer therapeutic agent via dual mechanisms DDR1 inhibition and methuosis induction.

Discovery of pyrazole derivative IHMT-140 as a pancreatic cancer therapeutic agent via dual mechanisms DDR1 inhibition and methuosis induction.

Journal: Journal of advanced research

Published: February 14, 2026

Discovery of Novel Purine Derivatives as Potent and Orally Bioavailable PGK1 Inhibitors for the Treatment of Inflammatory Bowel Disease.

Discovery of Novel Purine Derivatives as Potent and Orally Bioavailable PGK1 Inhibitors for the Treatment of Inflammatory Bowel Disease.

Journal: Journal of medicinal chemistry

Published: October 13, 2025

Discovery of a 1H-Pyrazol-3-Amine Derivative as a Novel, Selective, and Orally Available RIPK1 Inhibitor for the Treatment of Inflammatory Disease.

Discovery of a 1H-Pyrazol-3-Amine Derivative as a Novel, Selective, and Orally Available RIPK1 Inhibitor for the Treatment of Inflammatory Disease.

Journal: Journal of medicinal chemistry

Published: October 13, 2025

Targeting ROR1 with humanized antibody drug conjugates and cytokine fusion proteins for cancer therapy.

Targeting ROR1 with humanized antibody drug conjugates and cytokine fusion proteins for cancer therapy.

Journal: iScience

Published: September 17, 2025

Discovery of a Novel Dihydroisoquinolinone Derivative as a Potent CDK9 Inhibitor Capable of Overcoming L156F Mutant for the Treatment of Hematologic Malignancies.

Discovery of a Novel Dihydroisoquinolinone Derivative as a Potent CDK9 Inhibitor Capable of Overcoming L156F Mutant for the Treatment of Hematologic Malignancies.

Journal: Journal of medicinal chemistry

Published: April 08, 2025

Repurposing of clinical-stage FLT3 inhibitor HYML-122 as a potent RIPK2 inhibitor for the treatment of inflammatory bowel disease.

Repurposing of clinical-stage FLT3 inhibitor HYML-122 as a potent RIPK2 inhibitor for the treatment of inflammatory bowel disease.

Journal: International immunopharmacology

Published: February 10, 2025

Discovery of Pyrazolo[1,5-a]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors.

Discovery of Pyrazolo[1,5-a]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors.

Journal: Journal of medicinal chemistry

Published: August 20, 2024

Discovery of dihydropyridinone derivative as a covalent EZH2 degrader.

Discovery of dihydropyridinone derivative as a covalent EZH2 degrader.

Journal: European journal of medicinal chemistry

Published: July 26, 2023

Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor.

Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor.

Journal: European journal of medicinal chemistry

Published: May 29, 2023

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy.

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy.

Journal: Acta pharmaceutica Sinica. B

Published: March 15, 2023

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.

Journal: European journal of pharmacology

Published: February 25, 2023

Pharmacological inhibiting STAT5 for the treatment of FLT3-ITD-positive acute myeloid leukemia with triciribine phosphate monohydrate.

Pharmacological inhibiting STAT5 for the treatment of FLT3-ITD-positive acute myeloid leukemia with triciribine phosphate monohydrate.

Journal: MedComm

Published: February 25, 2023

Showing 1-12 of 49

Last Updated: 09/26/2026